HOPE Therapeutics, wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a binding Letter of Intent, LOI, to acquire a majority ...

The clinical-stage biopharmaceutical firm is pushing its NMDA platform while building a national network of psychiatric ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and full year 2024 earnings call. At this time, all lines are in a listen only mode. Following the presentation, we will ...

NRx Incorporated now owns two operating entities ... HOPE has signed nonbinding letters of intent to acquire three already profitable interventional psychiatry clinics. Our pipeline includes ...

a wholly owned subsidiary of NRx, signed non-binding letters of intent to acquire three precision psychiatry centers and is currently completing financial due diligence and definitive agreements.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, ...

Winpak Ltd. ("Winpak" or the "Corporation") announces today that the Toronto Stock Exchange (the "TSX") has accepted a notice filed by Winpak of its intention to renew its normal course issuer bid ...

AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management, announced today that it has initiated its ASCEND EV study. The prospective, ...

Analysts expect NRx Pharmaceuticals to post earnings of ($0.30) per share for the quarter. NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its earnings results on Friday, March 14th.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports.